Physician profile
Ephraim Keng
NPI 1457313892
$2,124.08
in general payments reported to CMS, 2019-2025
12 companies · $251 in 2025
The $251 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $24.06 · 2021: $711 · 2022: $154 · 2023: $562 · 2024: $157 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $970.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $434.10 | 2021-2024 | Grafix Pl |
| Kerecis Limited | $330.37 | 2021-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Organogenesis INC. | $291.58 | 2021-2023 | Puraply |
| Bayer Healthcare Pharmaceuticals INC. | $218.56 | 2022-2023 | |
| Wright Medical Technology, INC. | $154.41 | 2019 | |
| Dexcom, INC. | $132.29 | 2023 | Dexcom G7 Gss (161) |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $129.74 | 2025 | Lifevest |
| Merck Sharp & Dohme LLC | $121.38 | 2025 | Zerbaxa |
| Glaxosmithkline, LLC. | $119.52 | 2021 | |
| Kci USA, INC. | $111.14 | 2019 | |
| Abbott Laboratories | $56.93 | 2022 | |
| Amarin Pharma, INC. | $24.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ephraim Keng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.